Arcadia Biosciences, Inc.
RKDA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | – | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -10.5% | 21.3% | -1.3% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 32.1% | 43.4% | 43.2% | 32% |
| EBITDA | $0 | -$0 | -$0 | -$0 |
| % Margin | 65.9% | -102.1% | -100.6% | -185.7% |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | 65.7% | -306.4% | 216.6% | -334.2% |
| EPS Diluted | 0.62 | -3.26 | 1.9 | -1.18 |
| % Growth | 119% | -271.6% | 261% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |